London · Delayed Price · Currency is GBP · Price in GBX Kromek Group Earnings Call Transcripts
Fiscal Year 2026
-
CZT detector adoption in medical imaging is accelerating, with Kromek positioned to supply 40% of a $400M market by 2030. Profitability has been achieved, growth is underpinned by major contracts, and future expansion will be funded through debt and structured supply agreements.
Fiscal Year 2025
-
Profitability and revenue growth were driven by the Siemens deal, strong contract wins, and expanding CBRN and biosecurity segments. Gross margin rose to 81%, and the company targets £60M revenue and 30% EBITDA margin by 2030, with continued year-on-year profit expected.
-
Two clear growth pillars—advanced imaging and CBRN detection—are driving a midterm target of £60 million revenue and 30–35% EBITDA within five years, supported by strong contract wins, stable margins, and disciplined M&A. Focus remains on organic growth, operational excellence, and expanding in key global markets.
-
Two core segments—Advanced Imaging and CBRN Detection—are positioned for strong growth, supported by proprietary technology, high entry barriers, and robust customer relationships. FY2025 saw a shift to profitability, a strengthened balance sheet, and a clear midterm target of £60M revenue and 30% EBITDA.
-
Revenue grew 5% to £7.1m with gross margin up to 54%, and the business expects record full-year revenue and EBITDA positive results. Advanced imaging and CBRN segments both show strong growth, with robust pipelines and high revenue visibility for the year.